

Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.

Securities code: 2309
November 30, 2021

To our shareholders,

Kazuo Nakamura
Chairman & CEO
CMIC HOLDINGS Co., Ltd.
1-1-1 Shibaura, Minato-ku, Tokyo

Notice of the Convocation of the 37th Ordinary General Meeting of Shareholders

We are pleased to announce the 37th Ordinary General Meeting of Shareholders of CMIC HOLDINGS Co., Ltd. (the “Company”), which will be held as described below.

To mitigate the risk of infection of the novel coronavirus disease (COVID-19), you are strongly urged to refrain from traveling to the venue on the date of the meeting regardless of your own state of health. Shareholders who are elderly, have any underlying disease, or are pregnant are strongly requested to exercise careful judgment, as people in such conditions are perceived to be significantly affected by the infection. Instead of attending the meeting in person, you may exercise your voting rights in writing or via the internet, etc. Please review the attached “Reference Documents for the General Meeting of Shareholders” below to exercise your voting rights.

- 1. Date and time:** Wednesday, December 15, 2021 at 10:00 a.m.
- 2. Place:** Main Hall, Hamamatsucho Convention Hall (Nippon Life Hamamatsucho Crea Tower 5F)
2-3-1 Hamamatsucho, Minato-ku, Tokyo

3. Agenda:

Matters to be reported:

1. Report on the business report, the consolidated financial statements for the 37th fiscal year (from October 1, 2020 to September 30, 2021) and the results of the audit of the consolidated financial statements by the financial auditor and the Audit and Supervisory Board
2. Report on the non-consolidated financial statements for the 37th fiscal year (from October 1, 2020 to September 30, 2021)

Matters to be resolved:

- Proposal 1: Amendment to the Articles of Incorporation
Proposal 2: Election of Eleven (11) Corporate Directors

4. Exercise of voting rights by proxy:

If you exercise your voting rights by proxy, you may designate one other shareholder holding voting rights in the Company to attend the meeting. Please note, however, that it is necessary to submit a document proving the authority of the proxy.

Any modifications to the Reference Documents for the General Meeting of Shareholders will be posted on the Company’s website (<https://www.cmicgroup.com>; in Japanese only).

Reference Documents for the General Meeting of Shareholders

Proposal 1: Amendment to the Articles of Incorporation

1. Reason for the proposal

In order to prepare for the future business development and diversification of business activities of the Company and the Group, we propose that a business purpose be added to Article 2 (Purpose) of the current Articles of Incorporation, and that the item numbers be moved down in accordance with the establishment of the new items.

2. Details of the Changes

The changes are as follows:

(Underlined parts are the changes)

Current Articles of Incorporation	Proposed Amendments
<p>Article 2 (Purpose)</p> <p>1. The Company is organized for the purpose of engaging in the following businesses and controlling and managing the business activities of the companies (including foreign companies), associations (including those equivalent to associations in any foreign country), and other business entities similar thereto that engage in the following businesses by owning the shares or equity of such companies, etc.</p> <p>(1) – (23) (Text omitted) (Newly established)</p> <p>(Newly established)</p> <p>(Newly established)</p> <p>(24) – (25) (Text omitted)</p> <p>2. The Company aims to engage in any and all businesses ancillary or related to the preceding paragraph.</p>	<p>Article 2 (Purpose)</p> <p>(Unchanged)</p> <p>(1) – (23) (Unchanged)</p> <p><u>(24) Works related to the management and operation of hotels, training centers, and other lodging facilities and auxiliary facilities</u></p> <p><u>(25) Works related to the cultivation, processing and sale of agricultural products</u></p> <p><u>(26) Warehousing business</u></p> <p><u>(27) – (28)</u> (Unchanged)</p> <p>2. (Unchanged)</p>

Proposal 2: Election of Eleven (11) Corporate Directors

At the conclusion of this Ordinary General Meeting of Shareholders, the terms of office of all eleven (11) Corporate Directors will expire. In that regard, in order to further enhance the corporate governance and accelerate the globalization, the Company proposes to elect a total of eleven (11) Corporate Directors (of which, four (4) are to be External Corporate Directors), including two (2) new candidates (of which, one (1) is to be an External Corporate Director).

The candidates for Corporate Director are as follows:

Candidate No.	Name	Position in the Company	Candidate attributes		
1	Kazuo Nakamura	Representative Director, Chairman and CEO	Reelection		
2	Keiko Oishi	Representative Director, President and COO	Reelection		
3	Makoto Matsukawa	Corporate Director and CVO	Reelection		
4	Wataru Mochizuki	Corporate Director and CFO	Reelection		
5	Toru Fujieda	Corporate Director	Reelection		
6	Takeshi Hamaura	Corporate Director	Reelection		
7	Yoshiyuki Inamoto	Vice President	New election		
8	Masaru Iwasaki	External Corporate Director	Reelection	External	
9	Takeshi Karasawa	External Corporate Director	Reelection	External	Independent
10	Eriko Kawai	External Corporate Director	Reelection	External	Independent
11	Gregg Lindstrom Mayer	–	New election	External	Independent

Note: Ms. Keiko Oishi's name on the family register is Keiko Nakamura.

Candidate No. 1	<p>Reelection</p> <p>Number of the Company's shares owned: 564,220 shares Attendance to meetings of the Board of Directors: 12/12 (100%)</p>
<p>Kazuo Nakamura (December 17, 1946)</p>	<p>[Career summary, and position and responsibility in the Company]</p> <p>Apr. 1969 Joined Sankyo Co., Ltd. (currently Daiichi Sankyo Co., Ltd.) Mar. 1992 Representative Director and President, the Company Oct. 2003 Representative Director, Chairman and President CEO, the Company Dec. 2013 Representative Director, Chairman and President CEO, the Company (change of Japanese title only) Apr. 2018 Representative Director, Chairman and CEO, the Company Apr. 2021 Representative Director, Chairman and CEO, the Company (to present) (change of Japanese title only) Oct. 2021 Division Director of Healthcare Revolution Business, the Company (to present)</p> <p><i>Significant concurrent positions outside the Company:</i> Representative Director, Chairperson, harmo Co., Ltd.</p> <p>[Reasons for nomination as candidate for Corporate Director]</p> <p>After working in research and development at a large pharmaceutical corporation, Mr. Kazuo Nakamura founded the Company. He possesses outstanding abilities in executive management, which he has used to steer the Company as a leading company. As the Company expects him to continue to perform a decision-making and supervisory role in management, it again nominated him as a candidate for Corporate Director.</p>

Candidate No. 2	<p>Reelection</p> <p>Number of the Company's shares owned: 152,900 shares Attendance to meetings of the Board of Directors: 12/12 (100%)</p>
<p>Keiko Oishi (February 3, 1957) (Name on the family register: Keiko Nakamura)</p>	<p>[Career summary, and position and responsibility in the Company]</p> <p>Apr. 1982 Joined Nikkei/McGraw-Hill Inc. (currently Nikkei Business Publications, Inc.) Oct. 1989 Joined Genentech, Inc. Jan. 1996 Joined the Company July 2000 Corporate Director, the Company Oct. 2004 Corporate Director and Vice President, the Company Dec. 2010 Representative Director, the Company Apr. 2011 Representative Director, Corporate Officer, in charge of International Business, the Company Dec. 2013 Representative Director, Executive Vice President, Division Head of International Business Development Div., the Company Oct. 2016 Representative Director, Executive Vice President, CEO of CRO Business, Division Head of International Business Management Div., the Company Apr. 2018 Representative Director, President and COO, Supervisory Manager of Business Development & Marketing, the Company Apr. 2021 Representative Director, President and COO, CHO, Supervisory Manager of Business Development & Marketing, the Company Oct. 2021 Representative Director, President and COO, Division Director of CRO Business, the Company (to present)</p> <p><i>Significant concurrent positions outside the Company:</i> Representative Director, Chairperson, CMIC Co., Ltd. Representative Director, Chairperson, CMIC HealthCare Institute Co., Ltd. Representative Director and Vice President, CMIC ShiftZero K.K.</p> <p>[Reasons for nomination as candidate for Corporate Director]</p> <p>With extensive experience at international corporations, Ms. Keiko Oishi has been a member of the Company's senior management since the Company was founded, and she possesses outstanding abilities in executive management. During her time as President of the Company, her efforts toward "globalization" and "training of personnel for globalization" particularly stand out. As the Company expects her to continue to perform a decision-making and supervisory role in management, it again nominated her as a candidate for Corporate Director.</p>

Candidate No. 3	<p>Reelection</p> <p>Number of the Company's shares owned: 2,480 shares Attendance to meetings of the Board of Directors: 12/12 (100%)</p>
<p>Makoto Matsukawa (March 30, 1960)</p>	<p>[Career summary, and position and responsibility in the Company]</p> <p>Apr. 1984 Joined Akiyama Inc. (currently SUZUKEN CO., LTD.) Oct. 1989 Joined Baxter Limited June 1999 Joined Starbucks Coffee Japan, Ltd. Apr. 2007 Joined Quintiles Transnational Japan K.K. (currently IQVIA Services Japan K.K.) Jan. 2012 Joined the Company, Corporate Officer, in charge of Corporate Planning/IPD Dec. 2012 Corporate Director, Corporate Officer and IPD Company President, the Company May 2015 Senior Executive Officer, in charge of Business Development, the Company Oct. 2016 Senior Executive Officer, in charge of Business Development, CEO of CDMO Business, the Company Dec. 2016 Corporate Director, the Company Apr. 2018 Corporate Director and Executive Vice President, Supervisory Manager of CDMO, Supervisory Manager of CSO, the Company Nov. 2018 Corporate Director and Executive Vice President, Supervisory Manager of CDMO, the Company Apr. 2021 Corporate Director and CVO, Division Director of CDMO Business, the Company (to present)</p> <p><i>Significant concurrent positions outside the Company:</i> Representative Director & CEO, CMIC CMO Co., Ltd.</p> <p>[Reasons for nomination as candidate for Corporate Director] Having started up businesses in various industry sectors including not only the pharmaceutical sector, but also large-player service sector, Mr. Makoto Matsukawa possesses management experience and plays an instrumental role in globalization and strategic business development within the Company. As the Company expects him to continue to perform a decision-making and supervisory role in management, it again nominated him as a candidate for Corporate Director.</p>

Candidate No. 4	<p>Reelection</p> <p>Number of the Company's shares owned: 4,380 shares Attendance to meetings of the Board of Directors: 12/12 (100%)</p>
<p>Wataru Mochizuki (December 10, 1961)</p>	<p>[Career summary, and position and responsibility in the Company]</p> <p>Apr. 1985 Joined Nippon Oil & Fats Co., Ltd. (currently NOF CORPORATION) Jan. 1997 Joined Allied Telesis Holdings K.K. Aug. 2005 Joined the Company Oct. 2010 Corporate Officer, in charge of Internal Control/Information Disclosure/Finance and Accounting, the Company Dec. 2010 Corporate Director, the Company Oct. 2012 Corporate Director, Corporate Officer and CFO, in charge of Internal Control/Information Disclosure, the Company Oct. 2013 Corporate Director, Senior Corporate Officer and CFO, in charge of Finance and Legal Affairs Department/Internal Control/Information Disclosure, the Company May 2015 Corporate Director, Executive Vice President and CFO, in charge of Internal Control/Information Disclosure, the Company Apr. 2018 Corporate Director, Executive Vice President and CFO, Supervisory Manager of Administration and Support Unit, the Company Apr. 2021 Corporate Director and CFO, responsible for Group Information Disclosure/Internal Control, the Company (to present)</p> <p>[Reasons for nomination as candidate for Corporate Director]</p> <p>With extensive knowledge and experience in administrative departments, Mr. Wataru Mochizuki possesses outstanding abilities in executive management. As the Company expects him to continue to perform a decision-making and supervisory role in management, it again nominated him as a candidate for Corporate Director.</p>

Candidate No. 5	<p>Reelection</p> <p>Number of the Company's shares owned: 4,880 shares Attendance to meetings of the Board of Directors: 12/12 (100%)</p>
<p>Toru Fujieda (November 8, 1959)</p>	<p>[Career summary, and position and responsibility in the Company]</p> <p>Apr. 1984 Joined Sankyo Co., Ltd. (currently Daiichi Sankyo Co., Ltd.) June 2004 General Manager of Clinical Development Department, Sankyo Co., Ltd. Feb. 2016 Joined the Company, Senior Corporate Officer Corporate Director and Executive Vice President, CMIC Co., Ltd. Oct. 2016 President, CMIC Co., Ltd. (to present) Dec. 2016 Corporate Director and Executive Vice President, the Company Apr. 2018 Corporate Director and Executive Vice President, Supervisory Manager of Clinical CRO, the Company Apr. 2021 Corporate Director, Supervisory Manager of Clinical CRO, the Company Oct. 2021 Corporate Director, Deputy Division Director of CRO Business (in charge of Clinical CRO Business), the Company (to present)</p> <p><i>Significant concurrent positions outside the Company:</i> President, CMIC Co., Ltd.</p> <p>[Reasons for nomination as candidate for Corporate Director]</p> <p>With extensive experience in clinical development and management experience at a large pharmaceutical corporation, Mr. Toru Fujieda plays an instrumental role in the CRO business for the Company. As the Company expects him to continue to perform a decision-making and supervisory role in management, it again nominated him as a candidate for Corporate Director.</p>

Candidate No. 6	<p>Reelection</p> <p>Number of the Company's shares owned: 1,680 shares Attendance to meetings of the Board of Directors: 12/12 (100%)</p>
<p>Takeshi Hamaura (September 15, 1960)</p>	<p>[Career summary, and position and responsibility in the Company]</p> <p>Apr. 1985 Joined Sankyo Co., Ltd. (currently Daiichi Sankyo Co., Ltd.) Apr. 2012 Vice President of Supply Chain Technology Department, Daiichi Sankyo Co., Ltd. Apr. 2014 Vice President of CMC Planning Department, Daiichi Sankyo Co., Ltd. Apr. 2017 Head of Pharmaceutical Technology Division, Daiichi Sankyo Co., Ltd. Oct. 2019 Joined the Company, General Manager in charge of CDMO Business Promotion, Strategy Management Div. Nov. 2019 Executive Vice President and CTO, Assistant to Supervisory Manager of CDMO, the Company Dec. 2019 Corporate Director, the Company Apr. 2021 Corporate Director, Deputy Division Director of CDMO Business (to present)</p> <p><i>Significant concurrent positions outside the Company:</i> Representative Director and President, CMIC Bio Co., Ltd.</p> <p>[Reasons for nomination as candidate for Corporate Director]</p> <p>Mr. Takeshi Hamaura possesses extensive achievements and highly specialized knowledge of formulation technology development and in the CMC area. As the Company expects him to continue to perform a decision-making and supervisory role in management based on his business experience and achievements, it again nominated him as a candidate for Corporate Director.</p>

Candidate No. 7	<div data-bbox="505 190 639 219" data-label="Section-Header">New election</div> <div data-bbox="505 228 997 257" data-label="Text">Number of the Company's shares owned: – shares</div> <div data-bbox="505 257 1011 286" data-label="Text">Attendance to meetings of the Board of Directors: –</div>
<div data-bbox="212 560 475 622" data-label="Section-Header">Yoshiyuki Inamoto (June 12, 1952)</div>	<div data-bbox="505 295 1198 324" data-label="Section-Header">[Career summary, and position and responsibility in the Company]</div> <div data-bbox="505 329 1362 667" data-label="List-Group"> <ul style="list-style-type: none"> Apr. 1975 Joined Toray Industries, Inc. Apr. 1981 (Seconded to) Economic Planning Agency (currently Cabinet Office) Aug. 1990 Treasurer, Toray Industries (America), Inc. June 2003 General Manager, Finance Dept.; General Manager on Special Assignment, Corporate Strategic Planning Division, Toray Industries, Inc. June 2005 Member of the Board, General Manager, Corporate Strategic Planning Division, Toray Industries, Inc. June 2007 Director, in charge of Corporate Strategic Planning, Toray Industries, Inc. June 2011 Senior Director, Toray Industries, Inc. Nov. 2021 Joined the Company, Vice President (to present) </div> <div data-bbox="505 712 1145 741" data-label="Section-Header">[Reasons for nomination as candidate for Corporate Director]</div> <div data-bbox="505 745 1396 884" data-label="Text"> <p>Mr. Yoshiyuki Inamoto possesses extensive experience and management experience in finance, corporate planning and business development at a major chemical company. As the Company expects him to perform a decision-making and supervisory role in management based on his business experience and achievements, it has newly nominated him as a candidate for Corporate Director.</p> </div>

Candidate No. 8	<div style="display: flex; justify-content: space-between;"> Reelection External </div> <p>Number of the Company's shares owned: – shares Attendance to meetings of the Board of Directors: 12/12 (100%)</p>
<p>Masaru Iwasaki (May 3, 1947)</p>	<p>[Career summary, and position and responsibility in the Company]</p> <p>Dec. 1973 Joined Department of Surgery II, The University of Tokyo Hospital Apr. 1983 Joined Department of Surgery II, Faculty of Medicine, University of Yamanashi Apr. 1993 Joined Hoechst Japan Co., Ltd. (currently Sanofi K.K.) Jan. 2005 Joined GlaxoSmithKline K.K. Sept. 2011 Specially Appointed Professor, Department of Clinical Research, Faculty of Medicine, University of Yamanashi Sept. 2014 Specially Appointed Professor, Department of Advanced Biomedical Research, Faculty of Medicine, University of Yamanashi (to present) Apr. 2015 Vice President, University of Yamanashi (to present) Dec. 2016 External Corporate Director, the Company (to present)</p> <p><i>Significant concurrent positions outside the Company:</i> Vice President, University of Yamanashi Program Director, Japan Agency for Medical Research and Development Visiting Professor, Juntendo University School of Medicine</p> <p>[Reasons for nomination as candidate for External Corporate Director and summary of his expected role]</p> <p>After working as a clinician in the oncology area, Mr. Masaru Iwasaki possesses experience and achievements from serving in important positions for large pharmaceutical corporations in areas including product strategy planning and product development. He has performed an important role in the Company's management as an External Corporate Director from a technical perspective of pharmaceuticals and healthcare since December 2016. As the Company expects him to continue fulfilling the role of advising and supervising its overall management, it again nominated him as a candidate for External Corporate Director.</p>

Candidate No. 9	<div style="display: flex; justify-content: space-between; border-bottom: 1px solid black;"> Reelection External Independent </div> <p>Number of the Company's shares owned: – shares Attendance to meetings of the Board of Directors: 12/12 (100%)</p>
<p>Takeshi Karasawa (August 29, 1956)</p>	<p>[Career summary, and position and responsibility in the Company]</p> <p>Apr. 1980 Joined Ministry of Health and Welfare (currently Ministry of Health, Labour and Welfare)</p> <p>July 2000 Director, Public Relations Office, General Coordination Division, Minister's Secretariat, Ministry of Health and Welfare</p> <p>July 2004 Director, National Health Insurance Division and Director, General Affairs Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare</p> <p>July 2009 Deputy Director-General (in charge of Medical Insurance, Health Policy, Health Care and Long-term Care Integration), Ministry of Health, Labour and Welfare</p> <p>Sept. 2012 Director-General for Policy Planning and Evaluation (in charge of Social Security), Ministry of Health, Labour and Welfare</p> <p>July 2014 Director General, Health Insurance Bureau, Ministry of Health, Labour and Welfare</p> <p>June 2016 Director-General for Regional Revitalization, Headquarters for Overcoming Population Decline and Vitalizing Local Economy in Japan, Cabinet Secretariat</p> <p>Aug. 2016 Retired from Cabinet Secretariat</p> <p>Dec. 2018 External Corporate Director, the Company (to present)</p> <p><i>Significant concurrent positions outside the Company:</i></p> <p>Project Professor, Graduate School of Media and Governance, Keio University Outside Director, Value HR Co., Ltd.</p> <p>[Reasons for nomination as candidate for External Corporate Director and summary of his expected role]</p> <p>Mr. Takeshi Karasawa possesses extensive achievements and highly specialized knowledge of healthcare and nursing care related policies and the social security system in general from his experience in government administration. He has performed an important role in the Company's management as an External Corporate Director from an independent perspective since December 2018. In addition, as a Nomination and Remuneration Committee member, he proactively expresses his opinions and contributes to the deliberations of the Committee. As the Company expects him to continue providing us with practical advice on the Company's business strategy and promotion, it again nominated him as a candidate for External Corporate Director.</p>

Candidate No. 10	<div style="display: flex; justify-content: space-between; border-bottom: 1px solid black;"> <u>Reelection</u> <u>External</u> <u>Independent</u> </div> <p>Number of the Company's shares owned: – shares Attendance to meetings of the Board of Directors: 11/12 (92%)</p>
<p>Eriko Kawai (April 28, 1958)</p>	<p>[Career summary, and position and responsibility in the Company]</p> <p>Oct. 1981 Joined Nomura Research Institute, Ltd. Sept. 1985 Management Consultant, McKinsey & Company Oct. 1986 Fund Manager, Mercury Asset Management plc, SG Warburg Nov. 1995 Chief Investment Officer, Yamaichi Regent ABC Polska July 1998 Joined Bank for International Settlements Oct. 2004 Senior Pension Fund Administrator, Organisation for Economic Co-operation and Development (OECD) Mar. 2008 Representative, Kawai Global Intelligence Apr. 2012 Professor, Institute for the Promotion of Excellence in Higher Education, Kyoto University Apr. 2013 Professor, Institute for Liberal Arts and Sciences, Kyoto University Apr. 2014 Professor, Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University Dec. 2017 External Audit and Supervisory Board Member, the Company Dec. 2019 External Corporate Director, the Company (to present) Apr. 2021 Professor, Emeritus, Kyoto University (to present)</p> <p><i>Significant concurrent positions outside the Company:</i></p> <p>Specially Appointed Professor, Social Innovation Center, Graduate School of Advanced Integrated Studies in Human Survivability, Kyoto University Outside Director, Daiwa Securities Group Inc. Outside Director, Mitsui Fudosan Co., Ltd. Outside Audit & Supervisory Board Member, Yamaha Motor Co., Ltd.</p> <p>[Reasons for nomination as candidate for External Corporate Director and summary of her expected role]</p> <p>In addition to her extensive experience in international corporations, Ms. Eriko Kawai possesses experience and achievements as a corporate manager and outstanding knowledge in management. She has performed an important role in the Company's management as an External Corporate Director from an independent perspective since December 2019. In addition, as a Nomination and Remuneration Committee member, she proactively expresses her opinions and contributes to the deliberations of the Committee. As the Company expects her to continue providing us with practical advice on the Company's business strategy and promotion using her experience and knowledge, it again nominated her as a candidate for External Corporate Director.</p>

Candidate No. 11	<div style="display: flex; justify-content: space-between; border-bottom: 1px solid black;"> <input type="checkbox"/> New election <input type="checkbox"/> External <input type="checkbox"/> Independent </div> <p>Number of the Company's shares owned: – shares Attendance to meetings of the Board of Directors: –</p>
<p>Gregg Lindstrom Mayer (August 15, 1958)</p>	<p>[Career summary, and position and responsibility in the Company]</p> <p>June 1981 Co-Founder and Partner, BERKELEY ANTIBODY COMPANY, INC. Apr. 1983 President and Director, BERKELEY ANTIBODY COMPANY, INC. Jan. 1986 Joined VIVIGEN, INC. Jan. 1988 President, VIVIGEN, INC. Mar. 1993 Joined MCKINSEY & COMPANY June 1994 Director, UNM RAINFOREST INNOVATIONS (to present) Feb. 1995 President & CEO, GREGG L. MAYER & COMPANY, INC. (to present) Sept. 1996 Director, KAISER PERMANENTE INTERNATIONAL</p> <p><i>Significant concurrent positions outside the Company:</i> Director, DISEASE MANAGEMENT ASSOCIATION OF JAPAN Co-Chair, Population Health Research Committee ASIA PACIFIC SOCIETY FOR HEALTH SUPPORT SCIENCES</p> <p>[Reasons for nomination as candidate for External Corporate Director and summary of his expected role]</p> <p>Mr. Gregg Lindstrom Mayer possesses extensive experience and expertise in disease management, business development, etc. in the pharmaceutical, medical device, biotechnology and healthcare industries. He is also familiar with Japan's healthcare administration and the Company expects that he will be able to provide us with practical advice on the Company's global strategy and promotion. The Company therefore newly nominated him as a candidate for External Corporate Director.</p>

- Notes:
1. Special interest between the candidates and the Company:
 - (1) The Company makes donations to University of Yamanashi in which Mr. Masaru Iwasaki serves as Vice President.
 - (2) There is no special interest between the other candidates and the Company.
 2. Mr. Masaru Iwasaki, Mr. Takeshi Karasawa, Ms. Eriko Kawai and Mr. Gregg Lindstrom Mayer are candidates for External Corporate Director.
 3. Mr. Masaru Iwasaki is currently an External Corporate Director of the Company, and at the conclusion of this meeting, his tenure as External Corporate Director will have been five (5) years.
 4. Mr. Takeshi Karasawa is currently an External Corporate Director of the Company, and at the conclusion of this meeting, his tenure as External Corporate Director will have been three (3) years.
 5. Ms. Eriko Kawai is currently an External Corporate Director of the Company, and at the conclusion of this meeting, her tenure as External Corporate Director will have been two (2) years. While the Company also makes donations to the Kyoto University Graduate School, where she is a professor, according to the standards established by the Company, we judge that this does not affect her independence.
 6. The Company has entered into an agreement with Mr. Masaru Iwasaki, Mr. Takeshi Karasawa and Ms. Eriko Kawai to limit their liability amount to the minimum liability amount as provided for by Article 425, paragraph (1) of the Companies Act. If their reelection is approved, the Company plans to continue said limited liability agreement with each one of them. If the election of Mr. Gregg Lindstrom Mayer is approved, the Company plans to enter into the same limited liability agreement with him.
 7. The Company has submitted notification to the Tokyo Stock Exchange that Mr. Takeshi Karasawa and Ms. Eriko Kawai have been appointed as independent officers as provided for by the aforementioned exchange. Should their reelection be approved, the Company intends to submit notification that they have been appointed as independent officers. If the election of Mr. Gregg Lindstrom Mayer is approved, the Company plans to submit notification to the aforementioned exchange concerning his appointment as an independent officer.
 8. The Company has entered into a directors and officers liability insurance policy as provided for in Article 430-3, paragraph (1) of the Companies Act with an insurance company. In the event that an insured is claimed for damages by a shareholder or a third party in connection with the performance of their duties, the policy will cover losses including indemnification for such damages and litigation expenses. If this proposal is approved and adopted, and each of them is appointed as a Corporate Director of the Company, they will be included as insureds of the insurance policy. In addition, the Company plans to renew the policy with the same details at the next renewal.

<<Reference>> Skill Matrix of Candidates for Corporate Director and Audit and Supervisory Board Members

	Name	Corporate management	Finance/ Accounting	Legal affairs/ Risk management	Business knowledge	Global business
Corporate Directors	Kazuo Nakamura	●		●	●	
	Keiko Oishi	●			●	●
	Makoto Matsukawa	●			●	●
	Wataru Mochizuki	●	●	●		
	Toru Fujieda	●			●	●
	Takeshi Hamaura	●			●	●
	Yoshiyuki Inamoto	●	●			●
	Masaru Iwasaki			●	●	●
	Takeshi Karasawa	●		●	●	
	Eriko Kawai	●		●		●
	Gregg Lindstrom Mayer	●			●	●
Audit and Supervisory Board Members	Yasuo Yoshimune			●	●	
	Kei Hata			●		
	Hidetoshi Watanabe		●	●		
	Masaru Ota		●	●		

Note: The above list indicates up to three items that are particularly expected of each candidate, and does not exhaustively describe all the knowledge and experience possessed by each candidate.